Literature DB >> 22408249

Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.

Maike A Laussmann1, Egle Passante, Christian T Hellwig, Bartlomiej Tomiczek, Lorna Flanagan, Jochen H M Prehn, Heinrich J Huber, Markus Rehm.   

Abstract

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) can induce extrinsic apoptosis, resulting in caspase-8 activation, but may also initiate transcription-dependent prosurvival signaling. Proteasome inhibitors were suggested to promote TRAIL signal transduction through the death-inducing signaling complex (DISC) by modulating the relative abundance of core DISC components, thereby enhancing caspase-8 activation and apoptosis. To test this hypothesis, we quantified the changes in DISC protein levels as an early consequence of proteasome inhibition in HeLa cervical cancer cells and, based on these data, mathematically modeled the proapoptotic TRAIL signaling toward caspase-8 activation. Modeling results surprisingly suggested that caspase-8 activation might be delayed in presence of proteasome inhibitors, in particular at submaximal TRAIL doses. Subsequent FRET-based single cell time-lapse imaging at conditions where transcription dependent prosurvival signaling was blocked confirmed this hypothesis: caspase-8 activity was delayed by hours in the presence of proteasome inhibitors epoxomicin or bortezomib. Corresponding delays were detected for effector caspase processing and cell death. Contrary to current models, we therefore provide evidence that synergies between TRAIL and proteasome inhibitors do not result from changes in the levels of core DISC signaling proteins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22408249      PMCID: PMC3340270          DOI: 10.1074/jbc.M111.304378

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis.

Authors:  M Bentele; I Lavrik; M Ulrich; S Stösser; D W Heermann; H Kalthoff; P H Krammer; R Eils
Journal:  J Cell Biol       Date:  2004-09-13       Impact factor: 10.539

Review 2.  TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.

Authors:  Christian T Hellwig; Markus Rehm
Journal:  Mol Cancer Ther       Date:  2012-01       Impact factor: 6.261

3.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

Authors:  J C Cusack; R Liu; M Houston; K Abendroth; P J Elliott; J Adams; A S Baldwin
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

4.  Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.

Authors:  Fei Guo; Celia Sigua; Jianguo Tao; Purva Bali; Prince George; Yunqing Li; Sylvie Wittmann; Lynn Moscinski; Peter Atadja; Kapil Bhalla
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

5.  Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling.

Authors:  Nicholas Harper; Michelle A Hughes; Stuart N Farrow; Gerald M Cohen; Marion MacFarlane
Journal:  J Biol Chem       Date:  2003-08-14       Impact factor: 5.157

6.  The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

Authors:  Thomas J Sayers; Alan D Brooks; Crystal Y Koh; Weihong Ma; Naoko Seki; Arati Raziuddin; Bruce R Blazar; Xia Zhang; Peter J Elliott; William J Murphy
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

7.  Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8.

Authors:  Thomas S Söderström; Minna Poukkula; Tim H Holmström; Kaisa M Heiskanen; John E Eriksson
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

8.  Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.

Authors:  Qin He; Ying Huang; M Saeed Sheikh
Journal:  Oncogene       Date:  2004-04-01       Impact factor: 9.867

9.  The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.

Authors:  Thomas R Johnson; Kimberley Stone; Malti Nikrad; Tammie Yeh; Wei-Xing Zong; Craig B Thompson; Alexandre Nesterov; Andrew S Kraft
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

10.  NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP.

Authors:  Sebastian Kreuz; Daniela Siegmund; Jost-Julian Rumpf; Dierk Samel; Martin Leverkus; Ottmar Janssen; Georg Häcker; Oliver Dittrich-Breiholz; Michael Kracht; Peter Scheurich; Harald Wajant
Journal:  J Cell Biol       Date:  2004-08-02       Impact factor: 10.539

View more
  18 in total

Review 1.  Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?

Authors:  Heinrich J Huber; Ross G McKiernan; Jochen H M Prehn
Journal:  J Mol Med (Berl)       Date:  2014-01-30       Impact factor: 4.599

2.  Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging.

Authors:  Deborah A Flusberg; Peter K Sorger
Journal:  Phys Biol       Date:  2013-06-04       Impact factor: 2.583

3.  Protective effect of RIP and c-FLIP in preventing liver cancer cell apoptosis induced by TRAIL.

Authors:  Jichun Sun; Hongwu Luo; Wanpin Nie; Xundi Xu; Xiongying Miao; Feizhou Huang; Haiyan Wu; Xiaoxin Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

4.  Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold.

Authors:  Jérémie Roux; Marc Hafner; Samuel Bandara; Joshua J Sims; Hannah Hudson; Diana Chai; Peter K Sorger
Journal:  Mol Syst Biol       Date:  2015-05-07       Impact factor: 11.429

Review 5.  Modulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathways.

Authors:  M E Delgado; L Dyck; M A Laussmann; M Rehm
Journal:  Cell Death Dis       Date:  2014-01-23       Impact factor: 8.469

6.  Modeling dynamics of cell-to-cell variability in TRAIL-induced apoptosis explains fractional killing and predicts reversible resistance.

Authors:  François Bertaux; Szymon Stoma; Dirk Drasdo; Gregory Batt
Journal:  PLoS Comput Biol       Date:  2014-10-23       Impact factor: 4.475

7.  Model composition through model reduction: a combined model of CD95 and NF-κB signaling pathways.

Authors:  Elena Kutumova; Andrei Zinovyev; Ruslan Sharipov; Fedor Kolpakov
Journal:  BMC Syst Biol       Date:  2013-02-15

Review 8.  Systems biology of death receptor networks: live and let die.

Authors:  I N Lavrik
Journal:  Cell Death Dis       Date:  2014-05-29       Impact factor: 8.469

9.  2-DG-Regulated RIP and c-FLIP Effect on Liver Cancer Cell Apoptosis Induced by TRAIL.

Authors:  Yuping Zhang; Feizhou Huang; Jian Wang; Hongwu Luo; Zhichao Wang
Journal:  Med Sci Monit       Date:  2015-11-10

10.  MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1.

Authors:  Xu Sun; Yongqing Li; Meizhu Zheng; Wenshu Zuo; Wenzhu Zheng
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.